% 0期刊文章%一个克莱德马科维茨% Patricia Coyle %托马斯Leist %霍华德Zwibel Bruce Cohen % %马克Tullman % T女士治疗的持久性和治疗模式(P03.200) % D J神经病学2013% % P P03.200-P03.200 % V 80% N % X 7补充目的:评估使用超过三年的随访和治疗模式治疗多发性硬化症(MS)研首页究中优化(女士)。背景:与疾病修饰治疗安全性和有效性数据的积累(DMT)和女士的新疗法,治疗模式正在改变。设计/方法:潜在参与者的女士,一个前瞻性观察性研究,确定了在专业药房2008年12月开始。新生有MS诊断;一半被对待glatiramer醋酸(GA)和β干扰素(IFN)一半。签署知情同意被返回到药店。学习登记注销生产指令的学习网站,反应了。每个月DMT使用评估。治疗药物假期、持久性和更改记录(包括停止)和原因。结果:2530名参与者的至少一年的随访中,2293(90.6%)继续使用相同的不同。GA的用户比干扰素治疗持续(19.4 x平方分布;p < 0.004)。 Among those who persisted, 24 patients took drug holidays averaging 2.4 months (most often for financial reasons or common side effects) before resuming their DMT. Those who discontinued their initial DMT stopped for similar reasons. There were 172 therapy changes among 156 patients (6.2%): 32.6% of the changes originated with GA while 65.6% of the changes originated with IFN. Nearly 50% of DMT changes were to the newer therapies (natalizumab, INF beta-1b [Extavia], fingolimod); 29% to IFN and 22% to GA. Predominant reasons for changing therapies were ineffectiveness, worsening of symptoms, and doctor preferred a different medication.CONCLUSIONS: Persistence on the same DMT is high among patients on therapy for a year or more. For those with a change of therapy, there was a marked shift in prescribing toward the newer therapies in response to signs of therapy ineffectiveness.Supported by: Teva Pharmaceuticals.Disclosure: Dr. Markowitz has received personal compensation for activities with Bayer, Biogen-Idec, Eli Lilly, EMD-Serono, and Teva Neuroscience as a consultant. Dr. Coyle has received personal compensation for activities with Acorda Therapeutics, Bayer, Biogen Idec, Genentech, Inc., Novartis, Pfizer Inc, Questcor, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals Corporation, and Teva Neuroscience. Dr. Coyle has received personal compensation in an editorial capacity for NEURA. Dr. Coyle has received research support fromActelion, EMD Serono, and Novartis. Dr. Leist has received personal compensation for activities with EMD Serono, Teva Neuroscience, Biogen, Bayer, and Pfizer as a consultant. Dr. Leist has received research support from EMD Serono, Teva Neuroscience, Bayer, ONO, Novartis Daishi, Acorda. Dr. Cohen has received personal compensation for activities with Astellis, Biogen Idec, EMD Serono, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neurscience. Dr. Cohen has received research support from Teva Neuroscience, the National Institutes of Health, Biogen Idec, EMD Serono, Novartis, and Roche. Dr. Zwibel has received personal compensation for activities with Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Serono, Inc., Genentech, Inc., and Teva Neuroscience as a consultant and/or member of speaker bureau. Dr. Tullman has received personal compensation for activities with Allergan, Inc., Acorda Therapeutics, Biogen Idec, EMD Serono, Novartis, Pfizer Inc, Questcor, Teva Neuroscience, and Sanofi-Aventis Pharmaceuticals, Inc.Tuesday, March 19 2013, 2:00 pm-6:30 pm %U